newsfilter
← Latest News
Business Wire·

Aimmune Therapeutics Announces Third Quarter 2019 Financial Results and Provides Operational Highlights

BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced financial results for the quarter and nine months ended September 30, 2019 and provided operational highlights.